Health and Fitness Health and Fitness
Tue, July 26, 2011
Mon, July 25, 2011

Somaxon Pharmaceuticals to Report Second Quarter 2011 Results and Conduct Conference Call on Tuesday, August 2


Published on 2011-07-25 13:11:06 - Market Wire
  Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that it will release its second quarter 2011 financial results on Tuesday, August 2, 2011 after the closing of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the second quarter 2011.

The conference call will be available to interested parties through a live audio Internet broadcast at [ http://investors.somaxon.com/eventdetail.cfm ]. The call will also be archived and accessible at this site for approximately two weeks. Alternatively, callers may participate in the conference call by dialing (877) 941-6010 (domestic) or (480) 629-9643 (international), conference call ID 4459273. A telephonic replay will be available for approximately two weeks following the conclusion of the call by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international), and entering passcode 4459273.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxona™s product Silenor, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].

To be added to Somaxona™s e-mail list, please visit [ http://bit.ly/Somaxon-email-list ]

Contributing Sources